• JIG-SAW receives U.S. patent approval for the eyesight regeneration project:NEW-VISION technology(software-based cell control technology)in field of regenerative medicine

    Announcements

Jig-saw New-Vision technology

JIG-SAW receives U.S. patent approval for the eyesight regeneration project:NEW-VISION technology(software-based cell control technology)in field of regenerative medicine



JIG-SAW INC. (HQ: Tokyo, hereinafter “JIG-SAW”) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office with respect to the patent for software-based cell control technology (the eyesight regeneration project: NEW-VISION technology) in the field of regenerative medicine.

The patent will now come into effect via the prescribed procedure.

Title of invention
Head Mounted Type Video Presenting Device Including Visible Light Wavelength Converting Unit
Application Number
16/471,394
Filing Date
June 19, 2019

This is a groundbreaking initiative which aims to regenerate the eyesight of persons who have lost their sight due to retinal disease by using JIG-SAW’s proprietary wavelength converting software with an algorithm to control the color signals sent to cells.

To begin with, JIG-SAW plans to conduct clinical investigation of the device in conjunction with clinical trials of gene therapeutic agents used to treat diseases such as retinitis pigmentosa (*1).

JIG-SAW aims to combine the technology with gene therapeutic agents to enable those who have lost their eyesight due to a retinal disease to discern scenes and other persons’ faces and to read and write.

For further details about this initiative, please refer to JIG-SAW’s NEW-VISION website.
https://www.newvision-prj.com/

JIG-SAW continues to push ahead with completely unique regenerative medicine initiatives, such as registering patents and putting the technology to practical use in countries all around the world, in order to contribute the technology to as many people as possible.

*1
Retinitis pigmentosa is a retinal degenerative disease induced by an abnormal change in genes. It typically manifests in symptoms such as progressive night blindness, constriction of the visual field, and visual loss, and leads to a loss of color vision and eventual blindness.


JIG-SAW US, INC.
https://neqto.jig-saw.com/
156 2nd Street, San Francisco, CA 94105
Contact: inquiry@us.jig-saw.com

JIG-SAW INC.
https://www.jig-saw.com/
Listing: Tokyo Stock Exchange (Code: 3914)
Tokyo Head Office: 1-9-2 Otemachi, Chiyoda-ku, Tokyo
Tokyo | Sapporo | San Francisco | Santa Monica | Vancouver | Toronto
Representative: Masunaru Yamakawa, President & CEO